Journal article
Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid beta load in preclinical Alzheimer's disease
Lisa Bransby, Yen Ying Lim, David Ames, Christopher Fowler, Joanne Roberston, Karra Harrington, Peter J Snyder, Victor L Villemagne, Olivier Salvado, Colin L Masters, Paul Maruff
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY | TAYLOR & FRANCIS INC | Published : 2019
Abstract
Introduction: Preclinical Alzheimer’s disease (AD) is characterized by amyloid-related cognitive decline. Reduction in this decline is used to determine the efficacy of drug therapies designed to forestall the disease in preclinical AD clinical trials, measured by a Preclinical Alzheimer’s Cognitive Composite (PACC). Most studies estimate rates of cognitive change by comparing cognitively normal (CN) older adults with abnormally high beta-amyloid (Aβ+) to those with low levels (Aβ–). However, participants of preclinical AD clinical trials must be Aβ+ for entry. Therefore, we estimated the effect of very high amyloid (Aβ++) and Aβ+ on cognitive change over three years measured by different ve..
View full abstractGrants
Funding Acknowledgements
Funding for the study was provided in part by the study partners: Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research institute (MHRI), National Ageing Research Institute (NARI), Austin Health, CogState Ltd. The study also received support from the National Health and Medical Research Council (NHMRC); the Dementia Collaborative Research Centres program (DCRC2); the Science and Industry Endowment Fund (SIEF); and the Cooperative Research Centre for Mental Health (CRCMH); and the New Energy and Industrial Technology Development Organization (NEDO) Japan [grant to V.L.V.].